Drugs / XRD-0394
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06829173 | Nov 2025 → May 2027 expected | high grade astrocytic tumor | NYU Langone Health | Recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT05002140 | Aug 2021 → Jul 2023 | cancer, metastatic neoplasm | XRad Therapeutics Inc | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XRD-0394 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05002140 ↗ |
| Action | Inhibit | “dual inhibitor of ataxia telangiectasia mutated kinase (ATM) and deoxyribonucleic acid (DNA)-dependent protein kinase (DNA-PK)” NCT05002140 ↗ |
| Modality | Small molecule | “XRD-0394 is a novel, potent, oral, small molecule dual inhibitor” NCT05002140 ↗ |
| Route | Oral | “Administered orally” NCT06829173 ↗ |
| Target | ATM | “dual inhibitor of ataxia telangiectasia mutated kinase (ATM)” NCT06829173 ↗ |